2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Liquid Biopsy Innovations

Liquid biopsy represents a transformative approach in cancer diagnostics, utilizing minimally invasive blood samples to detect tumor-derived biomarkers like circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Unlike traditional biopsy methods, which require tissue samples, liquid biopsy offers a less invasive option for cancer detection. At the Cancer Research and Development Conference 2025, experts will explore how this cutting-edge technique revolutionizes the field by enabling early cancer detection, monitoring treatment response in real time, and identifying genetic mutations for more personalized therapies. As advancements in liquid biopsy continue to improve its accuracy and reliability, this technology is becoming an indispensable tool in cancer research, offering a glimpse into the future of precision medicine and improving patient outcomes through timely interventions.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno Oncology and Cell Based Therapies
Innovations in Immuno Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR T Cell Therapy: Clinical Progress and Challenges
Next Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy